Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Freshworks Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Freshworks Inc trades at $10.45 (market cap $2.86B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.9× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FRSH | |
|---|---|---|
Market Cap | $39.89B | $2.86B |
Sector | Health | Technology |
52-Week High | $491.22 | $14.77 |
52-Week Low | $278.09 | $6.88 |
Enterprise Value | $38.15B | $2.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FRSH trades at $10.36, down 0.38% on the day, with a bullish technical signal from moving averages and an overall analyst consensus split evenly between Buy and Hold. The company reported strong revenue growth to $838.81M in 2025, turning profitable with a net income of $183.72M, and recently announced Q2 2026 earnings will be released on August 4, 2026. Recent news highlights include a partnership with Vanquis and AI product enhancements.
Outlook remains positive with Wall Street projecting a 26% upside, supported by robust cash flow and margin expansion. Key risks include competitive pressures in SaaS and execution on AI initiatives. The stock presents a value opportunity given its P/E of 16.86 versus sector averages, but investors should monitor Q2 earnings for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
